Grifols, S.A. (ADR)
General ticker "GIKLY" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $12.4B (TTM average)
Grifols, S.A. (ADR) does not follow the US Stock Market performance with the rate: -20.7%.
Estimated limits based on current volatility of 1.8%: low 5.58$, high 5.79$
Factors to consider:
- Company pays dividends (irregularly): last record date 2025-08-12, amount 0.09$ (Y1.58%)
- Total employees count: 157 as of 2010
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.57$, 9.24$]
- 2026-12-31 to 2027-12-31 estimated range: [6.80$, 10.88$]
Financial Metrics affecting the GIKLY estimates:
- Positive: with PPE of 13.7 at the end of fiscal year the price was low
- Positive: Operating cash flow per share per price, % of 13.95 > 12.90
- Positive: 7.54 < Operating profit margin, % of 16.63
- Positive: Industry operating profit margin (median), % of 24.71 > 9.60
- Positive: Industry earnings per price (median), % of 5.49 > 4.45
- Negative: Industry operating cash flow per share per price (median), % of 5.61 <= 10.39
- Positive: 1.81 < Return on assets ratio (scaled to [-100,100]) of 1.92
- Positive: Inventory ratio change, % of -2.15 <= -0.75
Short-term GIKLY quotes
Long-term GIKLY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €6,591.98MM | €7,212.38MM | €7,524.00MM |
| Operating Expenses | €5,792.58MM | €6,020.37MM | €6,273.00MM |
| Operating Income | €799.40MM | €1,192.02MM | €1,251.00MM |
| Non-Operating Income | €-575.38MM | €-748.02MM | €-660.27MM |
| Interest Expense | €516.06MM | €773.15MM | €600.33MM |
| R&D Expense | €395.28MM | €384.04MM | €409.20MM |
| Income(Loss) | €224.02MM | €444.00MM | €590.73MM |
| Taxes | €43.35MM | €231.19MM | €110.09MM |
| Net Income(Loss)* | €59.31MM | €156.92MM | €386.03MM |
| Stockholders Equity | €5,827.17MM | €5,883.73MM | €5,269.53MM |
| Inventory | €3,459.28MM | €3,560.10MM | €3,294.45MM |
| Assets | €21,441.05MM | €21,405.24MM | €19,702.97MM |
| Operating Cash Flow | €208.28MM | €902.17MM | €1,005.68MM |
| Capital expenditure | €295.42MM | €371.37MM | €254.54MM |
| Investing Cash Flow | €-397.64MM | €886.67MM | €-556.15MM |
| Financing Cash Flow | €186.04MM | €-1,358.71MM | €-508.12MM |
| Earnings Per Share** | €0.04 | €0.12 | €0.28 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.